Robert Alter

Clinical trials

• A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

  Principal investigator · Completed · Phase 1, Phase 2

  MedImmune LLC

  2014–2020
• Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2025–2037
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  Site PI · Recruiting · Phase 2

  Alliance for Clinical Trials in Oncology

  2025–2034
• Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  Site PI · Recruiting · Phase 2, Phase 3

  National Cancer Institute (NCI)

  2024–2030